Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2111-2117

  Doehn, Jan M ^a   Fischer, Katja ^a   Reppe, Katrin ^a   Gutbier, Birgitt ^a   Tschernig, Thomas ^b   Hocke, Andreas C ^a   Fischetti, Vincent A ^c   Löffler, Jutta ^c   Suttorp, Norbert ^a   Hippenstiel, Stefan ^a   Witzenrath, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Aerosolized; Bacteriophage; Enzybiotics; Pneumococcus

Indexed keywords

ANTIINFECTIVE AGENT; CPL 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIOPHAGE; BODY WEIGHT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATORY INFILTRATE; LUNG; LUNG LAVAGE; MORPHOLOGY; MORTALITY; MOUSE; NONHUMAN; PLASMA CLEARANCE; STREPTOCOCCUS PNEUMONIA; SURVIVAL;

AEROSOLIZED; BACTERIOPHAGE; ENZYBIOTICS; PNEUMOCOCCUS;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BACTERIOPHAGES; BIOLOGICAL PRODUCTS; DISEASE MODELS, ANIMAL; ENDOPEPTIDASES; FEMALE; MICE; MICE, INBRED C57BL; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84882642002     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt131     Document Type: Article

References (38)

1. Williams BG, Gouws E, Boschi-Pinto C et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002; 2: 25-32.
2. O'Brien KL, Wolfson LJ, Watt JP et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
3. Jacobs MR, Felmingham D, Appelbaum PC et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from communityacquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-46.
4. Tleyjeh IM, Tlaygeh HM, Hejal R et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006; 42: 788-97.
5. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294: 2170-2.
6. Loessner MJ. Bacteriophage endolysins-current state of research and applications. Curr Opin Microbiol 2005; 8: 480-7.
7. Jun SY, Jung GM, Son JS et al. Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. Antimicrob Agents Chemother 2011; 55: 1764-7.
8. Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002; 418: 884-9.
9. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001; 98: 4107-12.
10. Cheng Q, Nelson D, Zhu S et al. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 2005; 49: 111-7. 11 Loeffler JM, Djurkovic S, Fischetti VA. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 2003; 71: 6199-204.
11. Loeffler JM, Djurkovic S, Fischetti VA. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 2003; 71: 6199-204.
12. Djurkovic S, Loeffler JM, Fischetti VA. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother 2005; 49: 1225-8.
13. McCullers JA, Karlstrom A, Iverson AR et al. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog 2007; 3: e28.
14. Jado I, Lopez R, Garcia E et al. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 2003; 52: 967-73.
15. Entenza JM, Loeffler JM, Grandgirard D et al. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 2005; 49: 4789-92.
16. Grandgirard D, Loeffler JM, Fischetti VA et al. Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis 2008; 197: 1519-22.
17. Witzenrath M, Schmeck B, Doehn JM et al. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit Care Med 2009; 37: 642-9.
18. Resch G, Moreillon P, Fischetti VA. A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance. Int J Antimicrob Agents 2011; 38: 516-21.
19. Schmeck B, Zahlten J, Moog K et al. Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promotor. J Biol Chem 2004; 279: 53241-7.
20. Reppe K, Tschernig T, Luhrmann A et al. Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia. Am J Respir Cell Mol Biol 2009; 40: 474-81.
21. Witzenrath M, Gutbier B, Schmeck B et al. Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia. Crit Care Med 2009; 37: 584-90.
22. Loeffler JM, Fischetti VA. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. Antimicrob Agents Chemother 2003; 47: 375-7.
23. Costa DL, Lehmann JR, Harold WM et al. Transoral tracheal intubation of rodents using a fiberoptic laryngoscope. Lab Anim Sci 1986; 36: 256-61.
24. Joukhadar C, Frossard M, Mayer BX et al. Impaired target site penetration of b-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29: 385-91.
25. Rohwedder RW, Bergan T, Thorsteinsson SB et al. Transintestinal elimination of ciprofloxacin. Diagn Microbiol Infect Dis 1990; 13: 127-33.
26. Badia JR, Soy D, Adrover M et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother 2004; 54: 508-14.
27. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
28. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358: 983-4.
29. Ghannam DE, Rodriguez GH, RaadII et al. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis 2009; 28: 253-9.
30. Michalopoulos A, Kasiakou SK, Mastora Z et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9: R53-9.
31. File TM Jr. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004; 117 Suppl 3A: 39S-50S.
32. Pallares R, Fenoll A, Linares J. The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. Int J Antimicrob Agents 2003; 22 Suppl 1: S15-24; discussion S25-6.
33. Fischetti VA, Nelson D, Schuch R. Reinventing phage therapy: are the parts greater than the sum?. Nat Biotechnol 2006; 24: 1508-11.
34. Murdoch DR, Laing RT, Mills GD et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001; 39: 3495-8.
35. Smith MD, Derrington P, Evans R et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003; 41: 2810-3.
36. Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002; 15: 95-110.
37. Garcia JL, Garcia E, Arraras A et al. Cloning, purification, and biochemical characterization of the pneumococcal bacteriophage Cp-1 lysin. J Virol 1987; 61: 2573-80.
38. Sheehan MM, Garcia JL, Lopez R et al. The lytic enzyme of the pneumococcal phage Dp-1: a chimeric lysin of intergeneric origin. Mol Microbiol 1997; 25: 717-25.